NEW APPROACHES TO TREATMENT OF GASTROINTESTINAL CANCER

在该计划项目的未来五年中，我们将继续 全力以赴，形成一个协调一致的整体 梅奥临床研究学科和相关实验室 以提高姑息治疗和治疗效果为目的的诊所 治疗人类胃肠道癌症。 以下 将讨论特定领域： 1) 结直肠癌的治疗 癌症。 2) 不太常见的胃肠道疾病的治疗 癌症和 3) 胃肠癌实验室科学。 我们继续特别重视发展和 测试局部疾病和手术的创新方法 以治愈为具体终点的辅助治疗。 小学的 重要性将是直接融入临床研究 癌症复杂实验室项目 药理学、细胞遗传学和免疫学。 我们将继续 利用该计划的特殊优势，其中包括 在胃肠道临床癌症方面拥有丰富的经验 研究；包括所有相关人员在内的专注临床研究团队 学科；癌症患者数量异常庞大 可在梅奥诊所进行有意义的研究 及时执行；独特的庞大人口 新诊断的胃肠道癌症允许进行 早期疾病研究；人口数量异常庞大 患有不太常见癌症的患者；与 的牢固关系 我们地区通过中北癌症中心的社区诊所 治疗组允许连续的管理和 利用相同的数据库扩大了 III 期试验；一口井 建立了梅奥癌症中心统计单位，其中涉及 在我们研究的所有阶段，以确保合理的方案设计， 一致的数据质量以及知情且客观的数据分析； 以及大量组织和实验室的现成可用性 基础实验室研究材料。 我们相信这些成分 结合我们既定的生产力和我们记录的 前两年半取得的成绩 赠款提供了最大的信心，表明拟议的工作将 符合最高科学标准，并将与 无与伦比的质量和成本效益。

Over the next five years of this Program Project we will continue to make strong efforts to bring together in a coordinated unit the clinical research disciplines and related laboratories of the Mayo Clinic for the purpose of improving both palliative and curative treatment of human gastrointestinal cancer. The following specific areas will be addressed: 1) Treatment of colorectal cancer. 2) Treatment of the less common gastrointestinal carcinomas and 3) Gastrointestinal Cancer Laboratory Science. We continue to place special emphasis on the development and testing of innovative approaches to regional disease and surgical adjuvant therapy with cure as a specific end point. Of primary importance will be the integration directly into clinical research programs of sophisticated laboratory endeavors in cancer pharmacology, cytogenetics and immunology. We will continue to utilize the particular strengths of this program which include an unexcelled depth of experience in gastrointestinal clinical cancer research; a devoted clinical research team including all concerned disciplines; the exceptionally large cancer patient population available at the Mayo Clinic permitting meaningful studies to be performed in a timely fashion; the uniquely large population of newly diagnosed gastrointestinal cancer permitting conduct of early disease studies; an extraordinarily large population of patients with less common cancers; strong relationships with community clinics in our region through the North Central Cancer Treatment Group permitting a continuum of management and expanded Phase III trials utilizing the same data base; a well developed Mayo Cancer Center Statistical Unit which is involved in all phases of our studies to insure sound protocol design, consistent data quality, and informed and objective data analysis; and ready availability of large amount of tissue and laboratory materials for basic laboratory study. We believe these ingredients combined with our established productivity and our documented accomplishment during the first two and one-half years of this grant provide maximum confidence that the work proposed will meet highest scientific standards and will be conducted with unexcelled quality and cost effectiveness.